EuroPCR 2024 | SOLVE-TAVI: Self Expanding or Balloon Expandable Valves?

This was a randomized study with 447 patients carried out to compare the 5-year evolution of TAVR using Evolut R and SAPIEN 3, as well as general anesthesia vs. conscious sedation. 

EuroPCR 2024

Randomization was in two stages: first valve selection and later the anesthesia technique, that is, conscious sedation vs general anesthesia.

The populations were similar.

Primary end point included all cause death, stroke, moderate regurgitation to severe, and the need for pacemaker implantation at 5 years. 

Five year outcomes did not show significant differences in primary outcomes (67.7% vs. 63.4%, p=0.34) between patients treated with Evolut R and SAPIEN 3, neither in all-cause mortality (48.5% vs. 47.6%), moderate to severe paravalvular leak (9% vs. 5.8%), or need for pacemaker implantation (29.6% vs. 22.8%). 

Read also: Catheter-Based Therapy for Pulmonary Embolism: Lower Mortality and Rehospitalization?

However, there was higher incidence of stroke in the group treated with SAPIEN 3 (4.8% vs. 0.5%, p=0.001). Also, there were no significant differences in primary end point when looking at the anesthesia technique, or events separately.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of valve type and anesthesia strategy for TAVI – 5-year results of the SOLVE-TAVI Trial.

Reference: Hans Josef Feistritzer.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...